Claims for Patent: 7,575,924

Summary for Patent: 7,575,924

Title:	Methods and compositions relating to improved lentiviral vectors and their applications
Abstract:	The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosaftey and promoters such as the EF1.alpha. promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.
Inventor(s):	Trono; Didier (Collonge, CH), Salmon; Patrick (Arenthon, FR)
Assignee:	Research Development Foundation (Carson City, NV)
Application Number:	10/010,081
Patent Claims:	1. A human hematopoietic cell transduced with a self-inactivating recombinant lentivirus, the lentivirus comprising an expression cassette comprising a transgene positioned under the control of a promoter that is capable of promoting expression of the transgene at a signal-to-noise ratio of between about 10 and about 200 in both a human hematopoietic progenitor cell and a differentiated hematopoietic cell; and an LTR region that has reduced promoter activity relative to wild-type LTR, wherein the human hematopoietic cell is a human hematopoietic progenitor cell. 2. The transduced cell of claim 1, wherein the recombinant lentivirus is further defined as incapable of reconstituting a wild-type lentivirus through recombination. 3. The transduced cell of claim 2, wherein the recombinant lentivirus does not express a functional lentiviral gene. 4. The transduced cell of claim 1, wherein the promoter is capable of promoting expression of the transgene at a signal-to-noise ratio of between about 40 and about 200. 5. The transduced cell of claim 4, wherein the promoter is capable of promoting expression of the transgene at a signal-to-noise ratio of between about 150 and about 200. 6. The transduced cell of claim 1, wherein the promoter is an EF1-.alpha. promoter, a PGK promoter, a gp91phox promoter, a MHC classII promoter, a clotting Factor IX promoter, a clotting Factor V111 promoter, an insulin promoter, a PDX1 promoter, a CD11 promoter, a CD4 promoter, a CD2 promoter or a gp47 promoter. 7. The transduced cell of claim 6, wherein the transgene is positioned under the control of the EF1-.alpha. promoter. 8. The transduced cell of claim 6, wherein the transgene is positioned under the control of the PGK promoter. 9. The transduced cell of claim 1, wherein the transgene is erythropoietin, an interleukin, a colony-stimulating factor, integrin .alpha.IIb.beta., a multidrug resistance gene, gp91phox, gp 47, an antiviral gene, a gene coding for blood coagulation factor VIII, a gene coding for blood coagulation factor IX, a T cell antigen receptor, a B cell antigen receptor, a single chain antibodies (ScFv), TNF, gamma interferon, CTLA4, B7, Melana, MAGE. 10. The transduced cell of claim 9, wherein the transgene is gp91phox. 11. The transduced cell of claim 9, wherein the transgene is gp 47. 12. The transduced cell of claim 9, wherein the transgene is Interleukin-2. 13. The transduced cell of claim 9, wherein the transgene is Interleukin-12. 14. The transduced cell of claim 9, wherein the transgene is a gene coding for blood coagulation factor VIII. 15. The transduced cell of claim 9, wherein the transgene is a gene coding for blood coagulation factor IX. 16. The transduced cell of claim 1, further comprising a posttranscriptional regulatory sequence positioned to promote the expression of the transgene. 17. The transduced cell of claim 16, wherein the posttranscriptional regulatory sequence is an intron positioned within the expression cassette. 18. The transduced cell of claim 17, wherein the intron is positioned in an orientation opposite the vector genomic transcript. 19. The transduced cell of claim 16, wherein the posttranscriptional regulatory sequence is a posttranscriptional regulatory element. 20. The transduced cell of claim 19, wherein the posttranscriptional regulatory element is woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). 21. The transduced cell of claim 20, wherein the posttranscriptional regulatory element is hepatitis B virus posttranscriptional regulatory element (HPRE). 22. The transduced cell of claim 1, wherein the LTR region has been rendered substantially transcriptionally inactive by virtue of deletions in the U3 region of the 3' LTR. 23. The transduced host cell of claim 1, wherein the human hematopoietic progenitor cell is a CD34.sup.+ cell. 24. A method for transducing a human hematopoietic stem cell comprising the steps of: (i) contacting a population of human cells that include hematopoietic stem cells in vitro with a lentiviral vector under conditions to effect the transduction of a human hematopoietic progenitor cell in said population by said vector, wherein the lentiviral vector is defined as a self-inactivating recombinant vector comprising: (a) an expression cassette comprising a transgene positioned under the control of a promoter that is that is capable of promoting expression of the transgene at a signal-to-noise ratio of between about 10 and about 200 in a differentiated hematopoietic cell active to promote detectable transcription of the transgene in a human hematopoietic progenitor cell; and (b) an LTR region that has reduced promoter activity relative to wild-type LTR; and (ii) differentiating the transduced stem cell into a differentiated hematopoietic cell. 25. The method of claim 24, wherein the human hematopoietic stem cell population comprises CD34.sup.+ cells. 26. The method of claim 24, wherein the cell population is treated to stimulate cell proliferation without substantial loss of stem cell pluripotency. 27. The method of claim 24, wherein the transduced stem cell is incubated in a differentiation media. 28. The method of claim 27, wherein incubated transduced stem cell is differentiated into an erythroid cell, a granulocyte, a monocyte or a dendritic cell. 29. The method of claim 28, wherein the incubated transduced stem cell is differentiated into a dendritic cell. 30. The method of claim 28, wherein the incubated transduced stem cell is differentiated into a granulocyte. 31. The method of claim 28, wherein the incubated transduced stem cell is differentiated into an erythroid cell. 32. The method of claim 28, wherein the incubated transduced stem cell is differentiated into a monocyte. 33. The method of claim 28, wherein the incubated transduced stem cell is differentiated into a B cell. 34. The method of claim 28, wherein the incubated transduced stem cell is differentiated into a T lymphocyte.

Details for Patent 7,575,924

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2020-11-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2020-11-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2020-11-13